Get the latest tech news
The World’s First Crispr Drug Gets a Slow Start
The first medical treatment to use Crispr gene editing has been on the market for a year. Its complexity means few patients in the US have received it yet.
Deshawn “DJ” Chow, 19, gets infused with Casgevy with pediatric hematologist-oncologist Dr Leo Wang while other members of his care team stand by at City of Hope Children’s Cancer Center. Stephan Grupp, section chief of cellular therapy and transplant at the Children’s Hospital of Philadelphia, says doctors will likely need to secure a single case agreement from insurers on behalf of their patients. Despite Casgevy’s slow start, Stuart Arbuckle, executive vice president and chief operating officer at Vertex, told WIRED in an emailed statement, “We are delighted with the strong first year of commercialization.” (The company declined an interview for this story.)
Or read this on Wired
